Resistant cells demonstrated global decreases in DNA accessibility with localized opening at resistance-driving loci, indicating non-mutational epigenetic reprogramming rather than canonical oncogenic ...

Researchers at City St. George’s, University of London, have identified a new molecular signature that may explain why patients with aggressive HER2-positive breast cancer developed resistance to ...

In this video, Azka Ali, MD, medical oncologist at the Cleveland Clinic Taussig Cancer Institute, highlights interesting research that has been presented at recent conferences.

More than a quarter of patients with ulcerative colitis do not receive prior advanced therapy before initiating mirikizumab, ...

We were honored to receive the 2025 Clinical Trials Arena R&D Excellence Award in the Precision Endocrine Therapy category, reflecting growing awareness of the utility of (Z)-endoxifen across oncology ...

As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily ...

Treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I under review.

Tenacia Biopharmac & Golden Age Health partner to commercialize Ztalmy for CDKL5 deficiency disorder in Mainland China: Shanghai Tuesday, February 3, 2026, 12:00 Hrs [IST] Tenacia ...

BACKGROUND: The disruption of the blood–brain barrier (BBB) is a central pathogenic event in many central nervous system disorders. However, the mechanisms regulating BBB function remain incompletely ...

Topical corticosteroids are recommended as first-line treatment for all levels of atopic dermatitis, as well as for maintenance therapy.